01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Medication-overuse headache is a secondary headache arising in a person with a pre-existing headache disorder during regular overuse of acute or symptomatic treatment. The clinical picture is often a gradual increase from discrete migraine or tension-type attacks to near-daily or daily pain, with acute medicines becoming less reliable. Diagnostic thresholds are class-specific: triptans, ergots, opioids and combination analgesics on at least 10 days per month, or simple analgesics such as paracetamol, aspirin and NSAIDs on at least 15 days, for more than 3 months, in someone with headache on at least 15 days monthly. Exposure to several classes can meet a multiple-drug threshold even when no single class seems excessive. The diagnosis is usually clinical and can be made prospectively while outcome after withdrawal clarifies causality.
History should reconstruct a typical month, not ask merely whether the person takes 'a lot'. Count headache days, migraine-feature days and days of each medicine, including caffeine combinations, opioid-containing prescriptions and remedies taken for neck or other pain. Establish dose escalation, morning use, anticipatory use and fear of being unable to work. Review sleep, mood, dependence, gastrointestinal or renal harm and the adequacy of prior acute and preventive care. Perform a neurological and funduscopic examination and rescreen for secondary features because chronic exposure does not immunise someone against a new intracranial disorder. Imaging is not routinely required when the phenotype is secure and examination is normal.
NICE recommends withdrawing all overused headache medicines for at least 1 month, advising that headache commonly worsens before improving and nausea, restlessness or sleep disturbance can occur. For most triptan, simple-analgesic and combination-analgesic overuse, abrupt outpatient withdrawal with information and support is appropriate. Strong opioids and complex dependence require specialist planning because withdrawal risks, comorbidity and safeguarding differ; an unmodified abrupt instruction may be unsafe. Arrange contact during the difficult first phase and a formal review after 4–8 weeks. A preventive for the underlying migraine or tension-type disorder may be offered alongside withdrawal, particularly when attack burden is high. Once the cycle improves, create a specific acute plan with use limits and early preventive review so relapse is not treated by renewed unrestricted supply.
Key points
- Suspect medication-overuse headache when headache is present on at least 15 days per month and one or more acute headache medicines have been overused for more than 3 months.
- Triptans, opioids, ergots and combination analgesics reach the overuse threshold at 10 or more days monthly; paracetamol, aspirin and NSAIDs reach it at 15 or more days.
- Count treatment days rather than tablet numbers, and include over-the-counter cold, pain and caffeine combinations that the patient may not regard as headache medicines.
- The underlying disorder is commonly migraine or tension-type headache; medication overuse is an interaction with that disorder, not evidence that the original headaches were unreal.
- NICE advises stopping all overused acute headache medicines for at least 1 month, usually abruptly, while explaining that headache often worsens temporarily and withdrawal symptoms can occur.
- Provide close follow-up and consider preventive treatment for the underlying primary headache alongside withdrawal according to headache type, comorbidity and preference.
- Do not routinely use inpatient withdrawal; consider specialist referral or inpatient care for strong opioid overuse, major comorbidity or repeated unsuccessful supported attempts.
- Review 4–8 weeks after withdrawal begins, then continue diary follow-up because improvement may evolve and relapse prevention requires a durable acute-treatment limit.
- Use non-judgemental language: repeated prescribing, delayed access to prevention and understandable attempts to remain functional often contribute to the cycle.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Underlying primary headache
Migraine and tension-type headache provide the usual biological substrate on which frequent rescue-medicine exposure increases headache frequency.
Frequent acute-medicine exposure
Triptans, opioids, ergots, combination analgesics and simple analgesics carry differing overuse patterns when taken regularly across many treatment days.
Care and behavioural contributors
Delayed access to prevention, fear of losing function, repeated large prescriptions and unrecognised over-the-counter combinations can sustain exposure without intentional misuse.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Repeated nociceptive modulation
Frequent acute treatment repeatedly alters trigeminovascular and descending pain-control systems in a person already susceptible to primary headache.
- 2Central sensitisation
Pain networks become more responsive and less able to filter ordinary sensory input, increasing background and attack-related headache.
- 3Withdrawal and reinforcement cycle
Temporary relief is followed by recurrence or withdrawal pain, prompting further dosing and reducing confidence in non-drug or preventive strategies.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Headache on at least 15 days monthly is the necessary background frequency; lower frequency does not meet medication-overuse-headache criteria even if prescribing is unsafe.
Use of triptans, opioids, ergot derivatives or combination analgesics on 10 or more days each month for over 3 months reaches the class threshold.
Paracetamol, aspirin or NSAID use on at least 15 days monthly for over 3 months can maintain medication-overuse headache.
Formerly discrete migraine or tension-type episodes may become more frequent, less predictable and less responsive, while still showing intermittent features of the underlying disorder.
Escalating strong opioid use, withdrawal between doses, multiple sedatives, severe mental illness or previous failed detoxification signals need for specialist support and sometimes inpatient care.
A new focal sign, papilloedema, systemic illness, abrupt peak or positional change is not accounted for by overuse and requires an independent urgent work-up.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Eight-week headache and treatment diaryFirst step - Why
- Count total headache days, migraine-feature days and exposure days for every acute medicine class.
- Interpretation and limitations
- Days rather than dose units determine thresholds; classify combination products and record medicines taken for non-headache pain that may still affect the cycle.
- 02
Complete medicines reconciliation - Why
- Find prescription, pharmacy, online and household products containing opioids, caffeine, paracetamol, aspirin or NSAIDs.
- Interpretation and limitations
- Brand names can conceal duplicate ingredients, and several classes may create overuse even when each is reported separately below its familiar threshold.
- 03
Neurological and funduscopic examination - Why
- Check that chronic headache remains consistent with the primary-plus-overuse formulation and lacks objective secondary signs.
- Interpretation and limitations
- Normal examination supports outpatient management; papilloedema, cognitive change or persistent deficit changes urgency and investigation.
- 04
Renal, liver, blood count and gastrointestinal assessment when indicated - Why
- Detect harm from sustained analgesic exposure and guide safe withdrawal or alternative treatment.
- Interpretation and limitations
- Choose tests from drug, dose and comorbidity rather than ordering a fixed panel; abnormal renal, hepatic, anaemia or bleeding findings need direct management.
- 05
Dependence and mental-health assessment - Why
- Identify opioid dependence, depression, anxiety, self-harm risk and practical barriers that determine withdrawal setting.
- Interpretation and limitations
- Strong-opioid dependence or major psychiatric and medical comorbidity supports specialist coordination rather than a minimally supported abrupt plan.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Chronic migraine
Frequent migraine can occur without overuse; a medicine-day history establishes whether rescue exposure is an important modifiable contributor.
Secondary progressive headache
New neurological signs, systemic disease, pressure features or abrupt change require investigation and should not be explained away by regular analgesic use.
Chronic tension-type headache
Bilateral pressure without migraine-associated symptoms may be chronic tension-type headache, with or without a superimposed overuse component.
Substance withdrawal headache
Caffeine, opioid or other withdrawal can cause short-lived headache linked to cessation rather than the established chronic overuse syndrome.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01IdentifyMake the hidden exposure visibleFirst stepHeadache has become frequent, chronic or progressively less responsive to rescue treatment.+
- 1Ask for total monthly headache days and reconstruct every acute treatment day using prescriptions, purchased products and medicines taken for other pain.
- 2Apply the correct 10-day or 15-day class threshold over more than 3 months, considering cumulative exposure to several classes.
- 3Confirm the likely underlying migraine or tension-type phenotype and perform red-flag and neurological assessment before attributing the whole pattern to overuse.
- 4Explain the mechanism as a reversible treatment-headache interaction, acknowledge prescribing-system contributions and agree that improvement requires a structured change.
02WithdrawSupport the difficult first monthMedication-overuse headache is diagnosed and outpatient withdrawal is clinically appropriate.+
- 1Agree a start date to stop all overused headache medicines for at least 1 month, usually abruptly, while adapting the plan if opioid dependence makes this unsafe.
- 2Prepare the person for transiently worse headache, nausea, sleep disruption or restlessness and provide clear contact routes and urgent safety advice.
- 3Consider starting or optimising prevention for the underlying headache and reinforce non-drug supports without replacing one frequent rescue medicine with another.
- 4Arrange early supportive contact and a formal 4–8-week review using the same diary measures that established the diagnosis.
03MaintainPrevent relapse after improvementHeadache frequency or treatment responsiveness improves following withdrawal.+
- 1Reclassify residual migraine and tension-type headache days and provide an effective route-specific acute plan with explicit monthly use limits.
- 2Continue or adjust prevention according to measured burden, tolerability and preference, avoiding an automatic return to large repeat quantities.
- 3EscalationIdentify early relapse signals such as anticipatory dosing, escalating pack use or lost diary recording and intervene before daily headache returns.
- 4Coordinate pharmacy and specialist care when multiple prescribers, chronic non-headache pain or dependence treatment could recreate exposure.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Chronic daily disability
Increasing headache days impair work, sleep, caring roles and mood and can make the original episodic disorder difficult to recognise.
Dependence and withdrawal harm
Opioid and combination-product use may create physiological dependence, difficult withdrawal and escalating healthcare use during repeated exposure.
Medicine-specific organ toxicity
Repeated analgesic exposure can cause gastrointestinal bleeding, kidney injury, liver toxicity or cardiovascular harm according to the medicine and comorbidity.
Relapse after withdrawal
Without an effective acute limit and preventive plan, renewed frequent rescue use can restore the sensitisation cycle after initial improvement.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Plot total headache days, migraine-feature days and treatment days weekly during withdrawal and monthly thereafter, using the same definitions each time.
- Monitor transient withdrawal symptoms, hydration, sleep, mood and ability to work or care, with an accessible plan when distress becomes difficult to manage.
- Review opioid withdrawal risk, autonomic symptoms and dependence needs separately from the headache diary when opioid-containing products were overused.
- At 4–8 weeks assess diagnostic fit, functional improvement, adverse effects of any preventive and whether a secondary feature has emerged.
- Audit repeat prescription quantities and over-the-counter access with the patient's agreement, ensuring that safe limits do not create abandonment or stigma.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Count days, not pills
Three tablets on one day count differently from single tablets on three days because repeated exposure across the month is the diagnostic pattern.
Several small streams combine
A patient alternating triptan, ibuprofen and a caffeine combination may underestimate total acute-treatment exposure when each brand is considered alone.
Worsening can be expected
Temporary deterioration after withdrawal does not mean the diagnosis or plan is wrong; anticipatory explanation and planned contact improve persistence.
Prevention can run alongside
Treating the underlying migraine while removing overused rescue medicines may improve feasibility, provided the preventive is selected and reviewed on its own merits.
Language affects success
Describing adaptation rather than blame respects why the patient sought relief and makes shared withdrawal more credible than accusing them of causing their pain.
11Common pitfallsFrequent interpretation and management errors.
- 01
Asking how many tablets are taken but not how many days per month are exposed, then missing the defining frequency pattern.
- 02
Counting prescribed triptans while ignoring pharmacy analgesics, caffeine combinations or opioid medicines used for another pain condition.
- 03
Giving an unsupported abrupt-stop instruction to someone dependent on strong opioids or sedatives without assessing withdrawal and comorbidity risk.
- 04
Replacing the withdrawn medicine with another acute drug used just as frequently and perpetuating the same cycle under a different name.
- 05
Assuming all chronic headache is overuse and failing to investigate new papilloedema, focal signs, systemic features or thunderclap pain.
- 06
Completing one month of withdrawal without a durable acute-treatment limit, prevention review or prescription plan to reduce relapse.